.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX09_Maraviroc.Maraviroc

Information

Maraviroc is an antiretroviral medication that acts as a CCR5 antagonist, used in combination therapy for the treatment of HIV-1 infection. It prevents viral entry into host cells by blocking the CCR5 co-receptor. Maraviroc is approved and currently in clinical use for HIV therapy.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after single oral administration.

References

1. Rosario, MC, et al., & van der Ryst, E (2008). Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients. British journal of clinical pharmacology 65 Suppl 1(Suppl 1) 86–94. DOI:10.1111/j.1365-2125.2008.03140.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18333870

2. Chan, PL, et al., & McFadyen, L (2008). A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. British journal of clinical pharmacology 65 Suppl 1(Suppl 1) 76–85. DOI:10.1111/j.1365-2125.2008.03139.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18333869

3. Weatherley, B, & McFadyen, L (2009). Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model. British journal of clinical pharmacology 68(3) 355–369. DOI:10.1111/j.1365-2125.2009.03455.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/19740392

Revisions

• 06/2025 initial generated model